• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Researcher Likely to Be Nominated to Lead the National Cancer Institute

Clinical Researcher Likely to Be Nominated to Lead the National Cancer Institute

July 25, 2022

A number of cancer organizations have voiced strong support for the Biden administration’s apparent pick for National Cancer Institute (NCI) director, Monica Bertagnolli, a distinguished surgical oncologist with a long career in clinical research.

It’s speculated that Bertagnolli, a surgical oncologist at the Dana-Farber Cancer Institute and professor of surgery at Harvard Medical School, will be selected to assume the role of permanent director at the NCI, though the White House has not yet confirmed its intention to nominate her. Bertagnolli would be the first woman to lead the institute if appointed.

Despite the lack of confirmation, several organizations, including the Association of American Cancer Institutes (AACI) and the American Society of Clinical Oncology (ASCO), where Bertagnolli previously served as president from 2018 to 2019, voiced support for her reported nomination.

The AACI noted her advocacy for improving diversity in cancer trials across the board, while ASCO praised her “deep expertise in community-based cancer research.” Similarly, Ned Sharpless, who resigned as the institute’s director at the end of April, also applauded Bertagnolli’s career in surgical oncology research.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 13Sep

    Trial Master File Inspection Readiness: From Chaos to Calm

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready? 

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 16Oct

    WCG MAGI's Clinical Research Conference 2022 West

  • 16Nov

    17th Annual FDA Inspections Summit

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Options-360x240.png

    Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

  • SurveywBlueBackground-360x240.png

    New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

  • Complexity-360x240.png

    Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

  • Challenge-360x240.png

    BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing